Reuters -- A federal court ruled on Tuesday that Merck & Co’s patent on Temodar, the world’s top-selling brain cancer drug, is unenforceable, possibly clearing the way for Teva Pharmaceutical Industries Ltd (TEVA.TA) to sell a generic form of the medicine.
